Related Experiment Video
Updated: Aug 13, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment
Bernd Löwe1, Irini Schenkel, Caroline Carney-Doebbeling
1Dept. of General Internal and Psychosomatic Medicine, Heidelberg Univ. Medical Center, Germany. bernd.loewe@med.uni-heidelberg.de
Abstract:
This is the first study that investigates the responsiveness of the Patient Health Questionnaire-9 (PHQ-9), a standard 9-item self-report depression scale, to antidepressant medication. Authors analyzed data from 1,788 depressed outpatients (66.8% women; mean age, 50.3 years), participating in a prospective, open-label, non-interventional, observational study of sertraline. On the 0-27-point PHQ-9 scale, the total sample gained 10.3 points at 12 weeks, corresponding to a standardized effect size of -1.85. With reference to two independent criterion standards, the PHQ-9 change scores were considerably greater in therapy responders than in nonresponders. The PHQ-9 was equally responsive in men and women. Therefore, the PHQ-9 qualifies as a practical tool for gauging response to pharmacological treatment in depressed patients.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Pharmacodynamic Responses: Different Types
Psychosis and Antipsychotic Drugs: Overview
Desensitization and Tachyphylaxis
Several...
